WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of HKD 135.14 billion. The enterprise value is 131.50 billion.

Market Cap	135.14B
Enterprise Value	131.50B

Important Dates

The last earnings date was Wednesday, August 20, 2025.

Earnings Date	Aug 20, 2025
Ex-Dividend Date	n/a

Share Statistics

WuXi Biologics has 4.07 billion shares outstanding. The number of shares has decreased by -2.55% in one year.

Current Share Class	4.07B
Shares Outstanding	4.07B
Shares Change (YoY)	-2.55%
Shares Change (QoQ)	-0.30%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	36.48%
Float	3.55B

Valuation Ratios

The trailing PE ratio is 30.65 and the forward PE ratio is 24.62. WuXi Biologics's PEG ratio is 1.29.

PE Ratio	30.65
Forward PE	24.62
PS Ratio	6.15
PB Ratio	2.51
P/TBV Ratio	2.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.29

Enterprise Valuation

EV / Earnings	28.60
EV / Sales	5.98
EV / EBITDA	17.83
EV / EBIT	21.86
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.

Current Ratio	2.88
Quick Ratio	2.40
Debt / Equity	0.10
Debt / EBITDA	0.76
Debt / FCF	n/a
Interest Coverage	31.72

Financial Efficiency

Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.64%.

Return on Equity (ROE)	10.50%
Return on Assets (ROA)	5.89%
Return on Invested Capital (ROIC)	6.64%
Return on Capital Employed (ROCE)	10.57%
Revenue Per Employee	1.75M
Profits Per Employee	366,331
Employee Count	12,575
Asset Turnover	0.34
Inventory Turnover	6.36

Taxes

In the past 12 months, WuXi Biologics has paid 1.35 billion in taxes.

Income Tax	1.35B
Effective Tax Rate	20.03%

Stock Price Statistics

The stock price has increased by +215.59% in the last 52 weeks. The beta is 0.50, so WuXi Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	+215.59%
50-Day Moving Average	29.05
200-Day Moving Average	23.14
Relative Strength Index (RSI)	61.44
Average Volume (20 Days)	53,733,764

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of HKD 21.98 billion and earned 4.60 billion in profits. Earnings per share was 1.08.

Revenue	21.98B
Gross Profit	9.37B
Operating Income	6.02B
Pretax Income	6.74B
Net Income	4.60B
EBITDA	7.38B
EBIT	6.02B
Earnings Per Share (EPS)	1.08

Balance Sheet

The company has 13.74 billion in cash and 5.60 billion in debt, giving a net cash position of 8.14 billion or 2.00 per share.

Cash & Cash Equivalents	13.74B
Total Debt	5.60B
Net Cash	8.14B
Net Cash Per Share	2.00
Equity (Book Value)	53.76B
Book Value Per Share	12.11
Working Capital	17.49B

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.

Gross Margin	42.65%
Operating Margin	27.38%
Pretax Margin	30.69%
Profit Margin	20.92%
EBITDA Margin	33.57%
EBIT Margin	27.38%
FCF Margin	n/a

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.55%
Shareholder Yield	2.55%
Earnings Yield	3.40%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.

Last Split Date	Nov 16, 2020
Split Type	Forward
Split Ratio	3

Scores

Altman Z-Score	n/a
Piotroski F-Score	5